SCHEMBL2376652

SCHEMBL2376652

COc1ccc(-c2nc(N3CCOCC3)nc(O)c2CCCO)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
MAPK1 P28482 3/20 0.51
ALOX15 P16050 3/20 0.51
GAA P10253 2/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HSD17B10 Q99714 5/20 0.50
KDM4E B2RXH2 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 7/20 0.46
KMT2A Q03164 7/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 2/20 0.46
TAAR1 Q96RJ0 1/20 0.45
CYP1A2 P05177 5/20 0.45
PIK3CA P42336 4/20 0.44
CASP1 P29466 4/20 0.44
CASP7 P55210 4/20 0.44
USP2 O75604 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2379106 0.88 PIK3CA (0.55) ALDH1A1MAPK1HSD17B10MEN1KMT2A
SCHEMBL2376647 0.83 MEN1 (0.48) ALDH1A1MAPK1ALOX15HPGDSMN1; SMN2
SCHEMBL2376722 0.81 PIK3CA (0.56) ALDH1A1MAPK1HSD17B10MEN1KMT2A
SCHEMBL27781488 0.76 MEN1 (0.50) ALDH1A1MAPK1ALOX15HPGDSMN1; SMN2
SCHEMBL11751124 0.74 TSHR (0.68) ALDH1A1MAPK1ALOX15GAAHPGD
SCHEMBL9695483 0.73 ALDH1A1 (0.61) ALDH1A1MAPK1ALOX15GAAHPGD
SCHEMBL6736048 0.72 PIK3CA (0.66) ALDH1A1MAPK1ALOX15GAAHPGD
SCHEMBL2826920 0.71 HTT (0.44) ALDH1A1MAPK1GAAHPGDHTT
SCHEMBL6740893 0.69 MAPT (0.86) ALDH1A1MAPK1GAASMN1; SMN2KDM4E
SCHEMBL19623684 0.67 PIK3CA (0.55) ALDH1A1ALOX15HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 ALDH1A1 2102/4885MAPK1 52/4885ALOX15 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.